Abstract
Background
The use of bisphosphonates (BP) in breast cancer patients with bone metastases (BM) has been shown to reduce bone pain and lower the risk of skeletal-related events (SREs). Many practice guidelines exist for the use of BPs in patients with BM. Unfortunately, none clearly address whether the benefits of BP use apply equally to all subgroups of patients, the duration of therapy, and when to discontinue BP therapy. A questionnaire was therefore developed and administered to determine how medical oncologists in Canada use BPs in clinical practice.
Methods
A structured mailing strategy was adopted. The population consisted of 100 medical oncologists with active breast cancer practices in Canada. All regions of Canada were represented. The questionnaire was developed to capture data on respondent demographics, BPs used, major factors influencing decision making, and clinical practice in situations where there is a lack of high-quality data.
Results
Completed questionnaires were returned by 76 medical oncologists. All treated breast cancer and the majority (68%) were based at teaching hospitals. Ninety-six percent of respondents regularly prescribed BPs, initiating therapy at the time the patient presented with BM. Although 79% of respondents recognized that there was no clear data to support the continued use of BP after bony progression, 53% stated that they rarely or never discontinue a BP once started. In situations where a BP was discontinued, the majority of respondents report the reason for discontinuation was a decrease in patient performance status. In the patient with clearly progressive visceral metastases and an estimated prognosis of less than 6 months, 75% of respondents would still commence BP therapy.
Conclusions
This study confirms that most medical oncologists in Canada, while acknowledging lack of evidence, maintain patients on BP therapy when patients have an expected survival of less than 6 months or even after patients progress while on a BP. More research is needed to determine the role of continuing, switching, or discontinuing BP therapy in the context of disease progression or shortened expected survival.
Similar content being viewed by others
References
Bloomfield D, Warr D, Whelan T, Pritchard K, Levine M (1999) Use of bisphosphonates in patients with bone metastases from breast cancer. Current Oncology 6:144–154
Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10(5):399–407
Breast Cancer Disease Site Group. Use of bisphosphonates in patients with bone metastases from breast cancer. CCO Practice Guideline Initiative. Available from: URL: www.hiru.mcmaster.ca/ccopgi/guidelines/bre/cpg1_11.html
Cancer Care Ontario (2000) New drug funding program. Available from: URL: www.cancercare.on.ca/treatment/newdrugs.html.
Coleman R (1997) Skeletal complications of malignancy. Cancer 80:1588–1594
Coleman R, Rubens R (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66
Coleman R, Smith P, Rubens R (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77:336–340
Hill M, Richards M, Gregory W, Smith P, Rubens R (1993) Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 68:969–973
Hillner BE, Ingle JN, Chelebowski RT et al (2003) American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042–4057
Hortobagyi G, Theriault R, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038–2044
Hortobagyi G, Theriault R, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. NEJM 335:1785–1791
Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090
Major P, Cook R, Tozer R, Hirte H (1998) Bisphosphonates for bone metastases in breast cancer patients: trial design issues and evaluation of published studies. Current Oncology 5:181–187
Mundy G (1997) Mechanisms of bone metastasis. Cancer 80:1546–1556
Rubens R (1998) Bone metastases—the clinical problem. Eur J Cancer 34:210–213
Theriault RL, Lipton A, Hortobagyi GN et al (1999) for the Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17(3):846–854
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verma, S., Kerr-Cresswell, D., Dranitsaris, G. et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists. Support Care Cancer 12, 852–858 (2004). https://doi.org/10.1007/s00520-004-0671-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-004-0671-9